Key result
In a real-world registry of NSTEMI patients, fondaparinux was associated with a significantly lower risk of severe in-hospital bleeding compared to low-molecular-weight heparin (OR 0.54).
Why the study?
Does fondaparinux reduce bleeding and death compared to low-molecular-weight heparin in patients with NSTEMI?
Cohort (n=40,616)
Yes
Does fondaparinux reduce bleeding and death compared to low-molecular-weight heparin in patients with NSTEMI?
Odds Ratio: 0.54 (95% CI 0.42–0.7)
Absolute Event Rate: 1.1% vs 1.8%
Real-world registry data confirms that fondaparinux is associated with lower risks of bleeding and death compared to LMWH in patients with NSTEMI, supporting its use as first-line therapy.
May inform fondaparinux selection to limit bleeding in NSTEMI; leaves open randomized confirmation.
The pivotal Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) trial demonstrated that fondaparinux was non-inferior to enoxaparin in reducing ischaemic outcomes in patients with a non-ST segment elevation myocardial infarction (NSTEMI). However, fondaparinux was associated with a lower number of patients experiencing major bleeding events. Based on these results suggesting a better benefit-to-risk ratio over enoxaparin, the European Society of Cardiology recommended fondaparinux as the first-line anticoagulation therapy in patients with an NSTEMI in 2007. A registry study conducted in Sweden provides real-life clinical data and confirms the clinical relevance of fondaparinux use over low-molecular-weight heparin in routine clinical care. This article aims to review the place of fondaparinux in acute coronary syndrome patients, and to provide an analysis of clinical trial data along with real-life data.
No takes yet. Share an insight, caveat, or question.
Jernberg et al. (2015) conducted a cohort in Non-ST segment elevation myocardial infarction (NSTEMI) (n=40,616). Fondaparinux vs. Low-molecular-weight heparin (LMWH) was evaluated on Severe in-hospital bleeding (OR 0.54, 95% CI 0.42-0.70). In a real-world registry of NSTEMI patients, fondaparinux was associated with a significantly lower risk of severe in-hospital bleeding compared to low-molecular-weight heparin (OR 0.54).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: